|
Can Digitally Delivered First-line Osteoarthritis Treatment Improve Equal Access to Care
RECRUITINGSponsored by Joint Academy
Actively Recruiting
SponsorJoint Academy
Started2022-01-01
Est. completion2025-06-30
Eligibility
Age18 Years+
View on ClinicalTrials.gov →
NCT06148779
Summary
To improve chronically ill patients' health and quality of life, long-standing and continuous treatment is needed at an acceptable cost. The purpose of this study was to compare utilization of digital versus face-to-face delivered osteoarthritis (OA) treatment in the 21 different county councils of Sweden that are responsible for providing healthcare to the residents.
Eligibility
Age: 18 Years+
\* Patients in the Joint Academy database that had participated in the Joint Academy treatment program for OA and given their informed consent to participate in research. Inclusion criteria for the treatment program: * Radiographic and or clinical diagnosis of hip or knee OA from a physical therapist or physician (95% of all patients in previously published studies). Individuals without a prior diagnosis had clinical OA confirmed by an orthopaedic surgeon or physiotherapist via telephone (diagnosis according to National Institute for Health and Care Excellence (NICE) criteria and Swedish National Guidelines, and confirming the absence of any red flag symptoms), or if deemed necessary were recommended to seek face-to-face care before inclusion in the programme. * From October 1st 2021, all patients should have undergone a physical examination by doctor or physiotherapists before being able to enter the treatment.
Conditions4
ArthritisFirst Line TreatmentHealth Services AccessibilityOsteoarthritis
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
SponsorJoint Academy
Started2022-01-01
Est. completion2025-06-30
Eligibility
Age18 Years+
View on ClinicalTrials.gov →
NCT06148779